Join Ola Ojewumi, a patient and health advocate with Post-Transplant Lymphoproliferative Disorder (PTLD), who shares the difficulties she has faced as a Black disabled woman with chronic pain, including her experiences with racism and inequities in healthcare and how she has learned to advocate for herself and others.
At The Leukemia & Lymphoma Society (LLS), we celebrate every advancement toward our mission of curing blood cancer and improving the quality of life for patients and their families. Today’s reason to celebrate is the news that the U.S. Food and Drug Administration (FDA) has approved a new treatment for children with a rare type of cancer called ALK-positive anaplastic large cell lymphoma (ALCL). ALCL constitutes approximately 10-15% of non-Hodgkin lymphoma in the pediatric population...
In partnership with The LLS Blog invites Aaron, who was diagnosed with peripheral T-cell lymphoma (PTCL), to share his reflections on becoming a self-advocate throughout his cancer experience. Read his powerful first-hand account below.
Multiple myeloma (MM) made up close to 20% of all new blood cancer cases diagnosed in the US in 2019. This disease is characterized by the uncontrolled proliferation of abnormal monoclonal plasma cells in the bone marrow. As these abnormal cells grow in excess, they disrupt normal cell production, which can result in a range of complications, particularly in the bones, blood, kidney and immune system. People with multiple myeloma develop tumors in more than one location inside and sometimes o...
In March 2019 I began feeling off but I didn't know what it was. I thought perhaps it was a loss of relationship that broke me to my core or that fact that an old friend had asked me to be kidney donor for someone I had never known. I agreed to be tested to see if I was a possible match and I was. In October, it was discovered that a possible blood clot had formed from all of this. I was having continual pain in my right shoulder blade. After a series of trigger point infections, a last ditch...
We could all use a little holiday cheer this year. According to the Centers for Disease Control and Prevention (CDC), the safest way to celebrate the winter holidays is to celebrate at home with people who live with you. Blood cancer patients and survivors are not at greater risk of catching COVID-19, but a blood cancer diagnosis might put you at a greater risk of getting sicker if you do get the virus. While it is safest to gather only with those in your home, if you do plan to host or atten...
Women's Health after a Blood Cancer Diagnosis: Unique Concerns and What's Next A Virtual Education Program (NJ Region) January 11, 2021 6:00pm – 8:00pm (ET) https://www.lls.org/events/women%27s-health-after-a-blood-cancer-diagnosis Targeted Therapies in Non-Hodgkin Lymphoma A Virtual Education Program (Connecticut-Hudson Valley Region) January 12, 2021 6:00pm – 7:30pm (ET) https://www.lls.org/events/targeted-therapies-in-non-hodgkin-lymphoma Meet the E...
LLS has expanded its series of fact sheets on managing side effects to include: -Low Appetite and Weight Loss -Mouth and Throat -Nausea and Vomiting -Diarrhea and Constipation -Peripheral Neuropathy -Childhood Cancer Treatment on Learning -Memory and Concentration Problems in Adults -Skin, Nails, Hair and Mouth The fact sheets can be downloaded or ordered HERE. For additional support and resources, please contact an Information Specialist today!
Chimeric Antigen Receptor T-cell Therapy or CAR T-cell therapy is an immunotherapy where a patient's immune system t-cells are engineered to detect and kill cancer cells. Currently there are four FDA approved CAR T-cell therapies for blood cancers: Axicabtagene ciloleucel (YescartaTM) is FDA approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not other...
Surprise medical bills can reach tens of thousands of dollars and devastate patients and their families. Help protect patients from this practice now. Congressional leaders have one last chance to pass legislation to protect patients from surprise medical bills this year. These are the bills patients receive when, for instance, they get healthcare at an in-network facility but – unbeknownst to them – are seen by an out-of-network provider. LLS advocates have lobbied for a comprehens...
The Leukemia & Lymphoma Society (LLS) hears from blood cancer patients and caregivers each day about the profound effects of the pandemic on their cancer care and daily lives, including questions about COVID-19 vaccination and when they will be available to them. While it’s been an incredibly trying time, there is optimism ahead as the supply of vaccinations and rate of vaccination will continue to increase. Currently, two COVID-19 vaccines have been authorized by the U.S. Food &...
&media=https://www.lls.org/sites/default/files/National/orlowski.jpg){kind=link}
